Loading organizations...
§ Private Profile · Ann Arbor, MI, USA
Automated laboratory equipment for histology and pathology labs, automating the mounting of tissue sections onto glass slides.
Based in Ann Arbor, Michigan, Aquaro Histology develops automated laboratory equipment designed to streamline tissue sectioning and mounting for clinical pathology and histology laboratories. The company's primary hardware system, the Aquaro ASM, automates the transfer of paraffin tissue sections from microtome blades directly onto glass slides to replace manual histologist labor. Operating with an estimated 10 to 50 employees, the enterprise generates revenue through B2B sales of its specialized medical devices and proprietary consumables to hospitals, pharmaceutical companies, and biomedical research facilities. The hardware developer has raised $9.8 million in Series A funding to expand commercial operations, backed by institutional investors including Telegraph Hill Partners and the Michigan Angel Fund. Guided by Chief Executive Officer Alberto Elli and board member Jack T. Ball, Aquaro Histology was founded in 2011 by David Olson, Nolan Orfield, and Collin Rich.
Aquaro Histology has raised $10.0M across 1 funding round.
Aquaro Histology has raised $10.0M in total across 1 funding round.
Aquaro Histology has raised $10.0M in total across 1 funding round.
Aquaro Histology's investors include Telegraph Hill Partners.
Aquaro Histology is a biotechnology startup founded in 2013 in Ann Arbor, Michigan, specializing in automated solutions for histology laboratory workflows.[1][2][3][4] The company develops, manufactures, and sells innovative devices that streamline critical processes like microtomy, improving efficiency, quality, and consistency for histology labs.[1][2][4][5] It targets pathology labs and research facilities facing manual, error-prone tissue processing, with reported revenue of $1.6 million and a small team of about 2 employees, plus financing secured for commercialization.[3][4]
Aquaro Histology was founded in 2013 by Vincent A. Alessi and Nolan Orfield, who identified inefficiencies in traditional histology lab procedures.[1] Based in Ann Arbor, MI, the company emerged from a focus on automating key steps in tissue sample preparation, such as microtomy—a pivotal process in pathology diagnostics.[1][4] Early milestones include completing financing to support commercialization of their automated microtomy technology, marking a shift from development to market entry.[4]
Aquaro Histology stands out in the histology automation space through:
Aquaro Histology rides the wave of lab automation and precision pathology, driven by rising demand for faster diagnostics amid growing cancer rates and personalized medicine trends.[1][5] Timing aligns with advances in AI-assisted pathology and biotech digitization, where manual histology bottlenecks hinder scalability—market forces like labor shortages and regulatory pushes for reproducibility favor automated solutions.[2][4] By influencing histology efficiency, Aquaro contributes to the broader ecosystem of diagnostic tech, enabling quicker tissue analysis for research and clinical use without disrupting established lab setups.[3][5]
Aquaro Histology is poised for growth through expanded commercialization of its microtomy tech, potentially capturing share in the $5B+ global histology market amid automation surges.[4] Trends like AI integration in pathology and rising lab throughput needs will shape its path, with partnerships or acquisitions by larger medtech firms likely amplifying influence. As a streamlined player solving real lab pain points, it exemplifies how targeted biotech innovation accelerates diagnostics—watch for revenue scaling and new product launches to solidify its niche.
Aquaro Histology has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in November 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2017 | $10M Series A | Telegraph Hill Partners | — | Announced |